Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 109 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Peanut Allergy Clear all
Completed Phase 1 Interventional

Trichuris Suis Ova in Peanut and Tree Nut Allergy

NCT01070498
View directory record Official record
Conditions
Food Allergy
Interventions
Trichuris suis ova (TSO)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study

NCT00932828
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Peanut oral immunotherapy
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
9 Months to 36 Months
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects

NCT03070561
View directory record Official record
Conditions
Peanut Allergy, Immunotherapy, Pharmacokinetics
Interventions
sublingual film with peanut extract
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 30 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Omalizumab in the Treatment of Peanut Allergy

NCT00949078
View directory record Official record
Conditions
Food Allergy, Peanut Allergy
Interventions
omalizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 25, 2026, 5:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Peanut Introduction: Translation to Clinical Practice

NCT03019328
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut in diet
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
4 Months to 11 Months
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

NCT01084174
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Immediate Hypersensitivity
Interventions
Peanut powder, Peanut extract, Placebo extract, Placebo powder
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 1 Interventional

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286
View directory record Official record
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 25, 2026, 5:44 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders

NCT01212016
View directory record Official record
Conditions
Eosinophilic Gastroenteritis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Not applicable Interventional Results available

Predicting Peanut Anaphylaxis and Reducing Epinephrine

NCT05696236
View directory record Official record
Conditions
Anaphylaxis Food
Interventions
Transepidermal water loss (TEWL) monitor and stopping rules, Monitor (TEWL) without stopping rules
Device
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 5 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

NCT03211247
View directory record Official record
Conditions
Peanut Allergy
Interventions
Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo, Part B Viaskin Peanut 250 mcg, Part B Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
1 Year to 3 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 25, 2026, 5:44 AM EDT
Recruiting No phase listed Observational

Study of Oral Food Challenge Biomarkers (SAFER)

NCT07279467
View directory record Official record
Conditions
Allergy
Interventions
Oral Food Challenge (OFC): Peanut Protein
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of Xolair in Peanut Allergy

NCT00086606
View directory record Official record
Conditions
Allergy
Interventions
Xolair (omalizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
6 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 25, 2026, 5:44 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Evaluation of a Supervised Clinical Feeding Intervention

NCT06892132
View directory record Official record
Conditions
Peanut Allergies in Children
Interventions
Supervised feeding intervention, Handout
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Months to 6 Months
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 1 Interventional

Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients

NCT02960074
View directory record Official record
Conditions
Peanut Allergy
Interventions
Fecal Microbiota Capsule
Biological
Lead sponsor
Rima Rachid
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

NCT07015996
View directory record Official record
Conditions
Peanut Allergy
Interventions
Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Not applicable Interventional

Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy

NCT01074840
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut flour
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 25, 2026, 5:44 AM EDT
Active, not recruiting No phase listed Observational

Food Oral Immunotherapy for Peanut Allergy

NCT04222491
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut oral immunotherapy
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Months to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Not applicable Interventional

Immunotherapy for Peanut Allergy

NCT00429429
View directory record Official record
Conditions
Allergy
Interventions
Sublingual immunotherapy
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 35 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 25, 2026, 5:44 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults

NCT01274429
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut flour
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 25, 2026, 5:44 AM EDT
Completed No phase listed Observational

The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy

NCT01950533
View directory record Official record
Conditions
Peanut Allergy, Milk Allergy, Egg Allergy
Interventions
Oral food challenge
Procedure
Lead sponsor
National Jewish Health
Other
Eligibility
3 Years to 21 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 25, 2026, 5:44 AM EDT
Active, not recruiting Phase 1 Interventional

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

NCT06369467
View directory record Official record
Conditions
Food Allergy
Interventions
linvoseltamab, dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Tampa, Florida • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intervention to Reduce Early (Peanut) Allergy in Children

NCT04604431
View directory record Official record
Conditions
Food Allergy Peanut, Food Allergy in Infants
Interventions
iREACH CDS Tool
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
4 Months and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
30
States / cities
Arlington Heights, Illinois • Bloomington, Illinois • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Preventing Anaphylaxis With Acalabrutinib

NCT05038904
View directory record Official record
Conditions
Food Allergy, Food Allergy Peanut
Interventions
Acalabrutinib
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 1 Interventional

HAL-MPE1 Safety and Tolerability Study

NCT02991885
View directory record Official record
Conditions
Peanut Allergy
Interventions
HAL-MPE1, HAL-MPE1 placebo
Biological · Drug
Lead sponsor
HAL Allergy
Industry
Eligibility
5 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 25, 2026, 5:44 AM EDT